No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor

Journal of Clinical Pharmacology

Volumn 42, Issue 10, 2002, Pages 1116-1121

  Martin, Paul D ^a   Dane, Aaron L ^a   Nwose, Olise M ^a   Schneck, Dennis W ^a   Warwick, Mike J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN; ROSUVASTATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERLIPIDEMIA; MALE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRIMIDINES; SEX FACTORS; SULFONAMIDES;

EID: 0036786383     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002401382722     Document Type: Article

References (17)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
2. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al: Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease. N Engl J Med 1990;322(24):1700-1707.
3. Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88(5):504-508.
4. Nezasa K, Takeuchi M, Yukawa T, Kawahara M, Inazawa K, Hasegawa H, et al: Tissue specific distribution of S-4522, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, to the liver in rats [abstract]. Xenobiotic Metab Dispos 1998;13(Suppl.):S226.
5. Brown CDA, Windass A, Bleasby K, Lauffart B: Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C [abstract]. Atheroscler Suppl 2001;2(2):90(P174).
6. McCormick AD, McKillop D, Butters CJ, Miles GS, Baba T, Touchi A, et al: ZD4522-an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems [abstract]. J Clin Pharmacol 2000;40:1055.
7. Martin PD, Dane AL, Schneck DW, Warwick MJ: Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects [abstract]. J Clin Pharmacol 2000;40:1056.
8. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
9. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Current Events Trial Investigators. N Engl J Med 1996;335:1001-1009.
11. Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR: Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996;36:242-246.
12. Cheng H, Rogers JD, Sweany AE, Dobrinska MR, Stein EA, Tate AC, et al: Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharmaceutical Research 1992;9(12):1629-1633.
13. Mazzu A, Lettieri J, Kaiser L, Mullican W, Heller AH: Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers. J Clin Pharmacol 1998;38:715-719.
14. Isaacsohn J, Zinny M, Mazzu A, Lettieri J, Heller AH: Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults. Eur J Clin Pharmacol 2001;56(12):897-903.
15. Pan HY, Waclawski AP, Funke PT, Whigan D: Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 1993;27:1029-1023.
16. Scripture CD, Pieper JA: Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001;40(4):263-281.
17. Hull CK, Penman AD, Smith CK, Martin PD: Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass-spectrometric detection. J Chromatogr B Biomed Appl 2002;772:219-228.